Amrutanjan Health Care working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

48.25×	48.25×	45.92×	49.74×	54.98×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
42.29×	42.29×	41.89×	35.05×	34.26×
104.51×	104.51×	102.13×	89.00×	108.19×
−13.97×	−13.97×	−14.32×	−4.21×	−18.95×
3.09×	3.04×	2.19×	1.87×	1.93×
1.08×	1.08×	1.15×	1.16×	1.07×
0.62×	0.62×	1.00×	0.62×	0.48×
0.48×	0.48×	0.87×	0.54×	0.43×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

AMRUTANJAN₹493.00

Amrutanjan Health Care Limited

· Pharma & Health

₹ CrorePeersJAGSNPHARM NGLFINE SIGACHI LINCOLN SYNCOMF THEMISMED HESTERBIOMcap ₹1,425 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Inventory Days (DIO)	54.98	49.74	45.92	48.25	48.25
Receivable Days (DSO)	34.26	35.05	41.89	42.29	42.29
Payable Days (DPO)	108.19	89.00	102.13	104.51	104.51
Cash Conversion Cycle (days)	-18.95	-4.21	-14.32	-13.97	-13.97
Working Capital Turnover	1.93	1.87	2.19	3.04	3.09
Asset Turnover	1.07	1.16	1.15	1.08	1.08
Cash Conversion (CFO/Net Income)	0.48	0.62	1.00	0.62	0.62
CFO/EBITDA	0.43	0.54	0.87	0.48	0.48

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.